bioAffinity Technologies Inc. Warrant

bioAffinity Technologies, Inc. develops non-invasive diagnostic laboratory tests for early-stage lung cancer and other lung diseases using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development, and Laboratory Services. Its CyPath Lung test uses flow cytometry to analyze cell populations in sputum for characteristics indicative of lung cancer, including cancer and cancer-related cells shed from a lung tumor. The company collaborates with Brooke Army Medical Center to evaluate proprietary tests under development for identifying inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. Incorporated in 2014, bioAffinity Technologies is based in San Antonio, Texas.